Cellebrite DI Ltd. (CLBT) Financial Ratios
7 years of historical data (2019–2025) · Technology · Software - Infrastructure
EV/EBITDA
↑
41.79
↓-27% vs avg
5yr avg: 57.45
30Y Low34.0·High76.2
P/FCF
↓
21.06
↓-48% vs avg
5yr avg: 40.81
30Y Low17.5·High74.1
P/B Ratio
↓
7.13
↓-66% vs avg
5yr avg: 20.68
30Y Low9.3·High48.1
ROE
↓
19.1%
↑-100% vs avg
5yr avg: 11589.7%
30Y Low-153%·High19%
Debt/EBITDA
↓
0.29
↓-49% vs avg
5yr avg: 0.57
30Y Low0.2·High1.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLBT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cellebrite DI Ltd. trades at 44.5x earnings, 60% above its 5-year average of 27.9x, sitting at the 67th percentile of its historical range. Compared to the Technology sector median P/E of 27.7x, the stock trades at a premium of 61%. On a free-cash-flow basis, the stock trades at 21.1x P/FCF, 48% below the 5-year average of 40.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.4B | $4.5B | $4.6B | $1.6B | $852M | $1.3B | $2.0B | — |
| Enterprise Value | $3.3B | $4.4B | $4.4B | $1.5B | $780M | $1.1B | $1.8B | — |
| P/E Ratio → | 44.55 | 58.16 | — | — | 7.39 | 18.23 | 340.78 | — |
| P/S Ratio | 7.10 | 9.47 | 11.50 | 5.07 | 3.15 | 5.26 | 10.11 | — |
| P/B Ratio | 7.13 | 9.30 | 13.73 | 48.13 | 11.53 | — | 30.89 | — |
| P/FCF | 21.06 | 28.10 | 37.96 | 17.49 | 74.13 | 46.37 | 32.67 | — |
| P/OCF | 19.45 | 25.96 | 34.91 | 16.14 | 41.40 | 35.94 | 29.63 | — |
P/E links to full P/E history page with 30-year chart
CLBT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Cellebrite DI Ltd.'s enterprise value stands at 41.8x EBITDA, 27% below its 5-year average of 57.4x. The Technology sector median is 17.5x, placing the stock at a 139% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.26 | 11.05 | 4.53 | 2.88 | 4.67 | 9.45 | — |
| EV / EBITDA | 41.79 | 56.21 | 65.68 | 34.02 | 76.15 | 55.19 | 122.02 | — |
| EV / EBIT | 49.25 | 66.24 | 77.92 | — | 6.45 | 13.94 | 161.64 | — |
| EV / FCF | — | 27.47 | 36.48 | 15.63 | 67.84 | 41.14 | 30.54 | — |
CLBT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cellebrite DI Ltd. earns an operating margin of 14.0%. Operating margins have expanded from 10.2% to 14.0% over the past 3 years, signaling improving operational efficiency. ROE of 19.1% indicates solid capital efficiency. ROIC of 18.5% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.2% | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% | 80.6% | 79.2% |
| Operating Margin | 14.0% | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% | 4.7% | -0.9% |
| Net Profit Margin | 16.5% | 16.5% | -70.5% | -24.9% | 44.6% | 29.0% | 3.0% | -1.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 19.1% | 19.1% | -152.9% | -150.1% | 46642.9% | — | 9.4% | -3.2% |
| ROA | 9.6% | 9.6% | -46.3% | -17.3% | 32.5% | 20.3% | 1.8% | -0.7% |
| ROIC | 18.5% | 18.5% | 603.1% | — | 49.7% | — | — | — |
| ROCE | 13.8% | 13.8% | 16.9% | 14.0% | 0.6% | 7.7% | 4.8% | -0.8% |
CLBT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Cellebrite DI Ltd. carries a Debt/EBITDA ratio of 0.3x, which is very conservative (90% below the sector average of 2.9x). The company holds a net cash position — cash of $124M exceeds total debt of $23M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.03 | 0.41 | 0.21 | — | — | — |
| Debt / EBITDA | 0.29 | 0.29 | 0.16 | 0.33 | 1.50 | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.54 | -5.13 | -0.98 | — | -2.02 | -1.30 |
| Net Debt / EBITDA | -1.30 | -1.30 | -2.68 | -4.06 | -7.06 | -7.01 | -8.53 | -29.91 |
| Debt / FCF | — | -0.63 | -1.49 | -1.86 | -6.29 | -5.22 | -2.13 | -7.71 |
| Interest Coverage | — | — | 0.16 | — | 7.01 | 90.34 | 6.48 | -4.32 |
Net cash position: cash ($124M) exceeds total debt ($23M)
CLBT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.56x means Cellebrite DI Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.66x to 1.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.56 | 1.56 | 1.92 | 1.66 | 1.42 | 1.46 | 2.03 | 2.64 |
| Quick Ratio | 1.54 | 1.54 | 1.89 | 1.62 | 1.38 | 1.43 | 2.00 | 2.60 |
| Cash Ratio | 1.18 | 1.18 | 1.51 | 1.19 | 0.88 | 0.97 | 1.49 | 2.02 |
| Asset Turnover | — | 0.51 | 0.58 | 0.61 | 0.67 | 0.72 | 0.53 | 0.61 |
| Inventory Turnover | 9.89 | 9.89 | 7.00 | 5.36 | 4.99 | 6.54 | 7.97 | 9.05 |
| Days Sales Outstanding | — | 80.55 | 74.93 | 86.75 | 106.22 | 100.06 | 124.20 | 93.95 |
CLBT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cellebrite DI Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 2.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 7.7% | 0.5% | — |
| Payout Ratio | — | — | — | — | — | 140.1% | 173.0% | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 1.7% | — | — | 13.5% | 5.5% | 0.3% | — |
| FCF Yield | 4.7% | 3.6% | 2.6% | 5.7% | 1.3% | 2.2% | 3.1% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.7% | 0.5% | — |
| Shares Outstanding | — | $250M | $209M | $190M | $195M | $162M | $187M | $187M |
Peer Comparison
Compare CLBT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLBTYou | $3B | 44.5 | 41.8 | 21.1 | 84.2% | 14.0% | 19.1% | 18.5% | 0.3 |
 AXON | $34B | 282.7 | 1664.9 | 458.1 | 59.7% | -2.2% | 4.5% | -1.3% | 90.6 |
 VRNS | $3B | -25.4 | — | 25.0 | 79.1% | -23.5% | -24.5% | -11.0% | — |
 OSPN | $455M | 6.4 | 6.0 | 9.0 | 70.7% | 20.6% | 30.1% | 21.7% | 0.1 |
 NTCT | $3B | -7.6 | — | 13.1 | 78.3% | -44.7% | -21.3% | -19.3% | — |
 IIIV | $506M | 40.9 | 14.0 | 134.9 | 55.7% | 1.9% | 3.5% | 0.6% | 0.2 |
 SPSC | $2B | 23.2 | 11.3 | 14.0 | 64.2% | 15.7% | 10.2% | 12.2% | 0.1 |
 CACI | $11B | 22.0 | 14.6 | 22.5 | 8.9% | 8.9% | 13.5% | 9.2% | 3.5 |
 SAIC | $4B | 12.2 | 6.4 | 7.3 | 12.0% | 7.1% | 23.3% | 14.2% | 0.3 |
 LDOS | $17B | 11.8 | 8.8 | 10.2 | 17.7% | 12.3% | 30.9% | 17.1% | 2.5 |
 BAH | $13B | 10.6 | 10.6 | 14.3 | 54.8% | 11.4% | 91.2% | 24.3% | 2.7 |
| Technology Median | — | 27.7 | 17.5 | 19.2 | 48.5% | -0.6% | 2.4% | 2.9% | 2.9 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See CLBT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLBT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLBT vs AXON
Side-by-side business, growth, and profitability comparison vs Axon Enterprise, Inc..
Start ComparisonCLBT — Frequently Asked Questions
Quick answers to the most common questions about buying CLBT stock.
What is Cellebrite DI Ltd.'s P/E ratio?
Cellebrite DI Ltd.'s current P/E ratio is 44.5x. The historical average is 27.9x. This places it at the 67th percentile of its historical range.
What is Cellebrite DI Ltd.'s EV/EBITDA?
Cellebrite DI Ltd.'s current EV/EBITDA is 41.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 57.4x.
What is Cellebrite DI Ltd.'s ROE?
Cellebrite DI Ltd.'s return on equity (ROE) is 19.1%. The historical average is -55.5%.
Is CLBT stock overvalued?
Based on historical data, Cellebrite DI Ltd. is trading at a P/E of 44.5x. This is at the 67th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Cellebrite DI Ltd.'s profit margins?
Cellebrite DI Ltd. has 84.2% gross margin and 14.0% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Cellebrite DI Ltd. have?
Cellebrite DI Ltd.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.